4 10 48 https://ciencia.lugoneseditorial.com.ar/files/original/dba27c25125f3c7bcda181fe2c46927b.pdf abf1c90dbbfd089f1ec6e595e6c70e76 Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/hidroxiapatita-calcio/">https://lugoneseditorial.com.ar/novedades/dermatologia/hidroxiapatita-calcio/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Evaluation of 80 mg/ml calcium hydroxyapatite in the treatment of nasolabial folds. Analysis of durability, safety, and efficacy at 12 months Description An account of the resource Introduction: skin aging involves collagen fragmentation, which affects the extracellular matrix and accelerates deterioration. Photoaging, caused by ultraviolet radiation, motivates patients to seek corrective treatments. Calcium hydroxyapatite (CaHA) is a biocompatible filler that stimulates collagen production and provides safe and long-lasting results with a low complication rate. Correction of the nasolabial fold (NLF) is key to facial aesthetics, and CaHA has been shown to be effective in improving appearance and rejuvenating the face. Objectives: demonstrate the efficacy and safety of Cientific Permanent Facial Implant II® (CaHA 80 mg/ml) for the correction of mild to moderate NLF.1 Materials and methods: a multicenter, prospective, open-label, longitudinal clinical study included 122 patients of both sexes (35–65 years old) with mild to moderate nasolabial folds (NLF). A maximum of 1 ml of CaHA filler was applied per fold, with the possibility of reapplication after 9 months in selected cases clinical parameters of efficacy, safety, and duration of effect were assessed using validated scales at baseline and at 3, 6, 9, and 12 months. The Lemperle scale was used for the initial patient assessment, and improvements were also assessed using this scale and the Global Aesthetic Improvement Scale (GAIS) and photographs of each follow-up. Results: the study confirmed the safety and efficacy of Cientific Permanent Facial Implant II® (CaHA 80 mg/ml) for the correction of NLF, with mild adverse events such as pain, erythema, edema and ecchymosis, all transient and resolved spontaneously. At 12 months, the majority of patients maintained satisfactory results, with a high rate of improvement according to the GAIS scale. Only two patients were evaluated outside the protocol for asymmetries, and only one required correction. All participants attended the established follow-up visits, demonstrating adherence to the study and stability of the treatment. Conclusions: Cientific Permanent Facial Implant II® (CaHA 80 mg/ml) was shown to be an effective and safe treatment for the correction of mild to moderate NLF. Reapplication after 9 months optimizes the duration of the effect in certain patients Creator An entity primarily responsible for making the resource Ivanna Laura Salerno, Plastic Surgeon, Director of the Dr. Ivanna Salerno Center, City of Buenos Aires, Argentina. ORCID: <a href="https://orcid.org/0009-0004-5430-5683">https://orcid.org/0009-0004-5430-5683</a> Claudio Dachevsky, Plastic Surgeon, General Manager, Lipo Plastic Surgery Clinic, São Paulo, Brazil. ORCID: <a href="https://orcid.org/0009-0006-5400-0585">https://orcid.org/0009-0006-5400-0585</a> Source A related resource from which the described resource is derived Cientific Permanent Facial Implant II® Publisher An entity responsible for making the resource available Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 26/05/2025 Contributor An entity responsible for making contributions to the resource Cientific Permanent Facial Implant II® Identifier An unambiguous reference to the resource within a given context <a href="https://doi.org/10.47196/0596">https://doi.org/10.47196/0596</a> aesthetic medicine biostimulation CaHA calcium hydroxyapatite dermal fillers nasolabial folds https://ciencia.lugoneseditorial.com.ar/files/original/a99411b509f6b3485fb4c2272a46cd81.pdf 4c176201408ce815a005919d9835d6c2 Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-nasolabiales/">https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-nasolabiales/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Evaluation of the efficacy and safety of cross-linked hyaluronic acid 30 mg/ml for filling nasolabial folds Description An account of the resource Introduction: the nasolabial folds (NLF) are a highly mobile facial region that undergoes multifactorial changes during aging. Cientific Hyaluronic Facial Implant 30® is a 30 mg/ml cross-linked hyaluronic acid (HRA) filler developed to optimize the results of this highly dynamic facial area. Objectives: to evaluate the safety and efficacy of Cientific Hyaluronic Facial Implant 30® (CH30), composed of 30 mg/ml HRA, for the correction of moderate to severe NLF. Materials and methods: a 12-month, prospective, multicenter clinical study that included 64 male and female patients between 30 and 75 years of age with moderate to severe NLF treated in both NLFs with CH30 to balance the asymmetry until optimal correction was achieved. Efficacy assessments by evaluators included analysis of NLF severity using the Wrinkle Severity Rating Scale (WSRS) and improvement using the Global Aesthetic Improvement Scale (GAIS). Safety was recorded throughout the study based on checks at each appointment and patient reporting of adverse events. Results: no adverse events were observed during the 12-month follow-up. In 100% of cases, defect correction, duration, and satisfaction were rated by patients and physicians as “improved” to “very improved,” with a very slow decrease in effect observed at 12 months. Conclusions: the use of AHR for the treatment of NLF is one of the most effective and safe options in current aesthetic medicine. Its ability to restore volume, smooth wrinkles, and improve skin quality make it a key tool for facial rejuvenation. The durability of the results, combined with its low complication rate, makes HRA widely recommended for patients seeking a natural and longlasting aesthetic improvement, making it one of the most popular interventions in modern aesthetic medicine. Creator An entity primarily responsible for making the resource Claudio Dachevsky: Plastic Surgeon, General Manager, Lipo Plastic Surgery Clinic, São Paulo, Brazil Source A related resource from which the described resource is derived I. Russell-Goldman E, Murphy GF. The pathobiology of skin aging. New insights into an old dilemma. Am J Pathol 2020 Jul;190(7):1356-1369. doi: 10.1016/j. ajpath.2020.03.007. II. Lupo M. Hyaluronic acid fillers in facial rejuvenation. Seminars in cutaneous medicine and surgery 2006; 25:122-6. doi: 10.1016/j.sder.2006.06.011. III. Duranti F, Salti G, Bovani B, Calandra M, Rosati ML. Injectable hyaluronic acid gel for soft tissue augmentation. A clinical and histological study. Dermatol Surg 1998 Dec;24(12):1317-25. doi: 10.1111/ j.1524-4725.1998.tb00007.x. IV. Braccini F, Fanian F, García P, et al Comparative clinical study for the efficacy and safety of two different hyaluronic acid-based fillers with Tri-Hyal versus Vycross technology. A long-term prospective randomized clinical trial. J Cosmet Dermatol 2023. Feb;22(2):473-485. doi: 10.1111/jocd.15200. V. Peña F. Factores relacionados a la durabilidad del ácido hialurónico reticulado. Rev Facultad de Medicina de la Universidad de lberoamérica 2023;2;13-21. doi 10.54376/rcmui.v2i2.148. VI. Wongprasert P, Dreiss CA, Murray G. Evaluating hyaluronic acid dermal fillers. A critique of current characterization methods. Dermatol Ther 2022 Jun;35(6):e15453. doi: 10.1111/dth.15453. VII. Sánchez-Carpintero D, Ruiz-Rodríguez R. Materiales de relleno: tipos, indicaciones y complicaciones. Actas Dermosifiliogr 2010;101(5):381-393. VIII. Bukhari SNA, Roswandi NL, Waqas M, Habib H, Hussain F, et al. Hyaluronic acid, a promising skin rejuvenating biomedicine. A review of recent updates and pre-clinical and clinical investigations on cosmetic and nutricosmetic effects. Int J Biol Macromol. 2018 Dec;120(Pt B):1682-1695. doi: 10.1016/j. ijbiomac.2018.09.188. IX. Martínez-Carpio PA, Vega López PM. Materiales de relleno temporales en medicina estética: revisión de la literatura sobre la incidencia de efectos adversos y complicaciones. Medicina Estética 2019;59(2):14-19. doi: 10.48158/MedicinaEstetica.059.02 X. Cifuentes-Mimoso T, Signes-Soler F. Estudio de efectos adversos tras tratamiento con implantes cutáneos de ácido hialurónico. Universitat Autonoma de Barcelona. Disponible en: https://semcc.com/master/files/Hialuronico%20y%20efectos%20adversos%20-%20Dras.%20Cifuentes%20y%20Signes.pdf. XI. Robles M. Estudio de seguridad y eficacia del ácido hialurónico reticulado en relleno de surcos nasolabiales. doi: 10.47196/0573. XII. Bogdan-Allemann I, Baumann L. Hyaluronic acid gel (Juvéderm) preparations in the treatment of facial wrinkles and folds. Clin Interv Aging 2008;3(4):629-34. Doi: 10.2147/cia.s3118. XIII. Jordan DR. Delayed inflammatory reaction to hyaluronic acid (Restylane). Ophthalmic Plast Reconstr Surg 2005 Sep;21(5):401-2. doi: 10.1097/01.iop.0000173194.18050.b8. XIV. NASHATM. The monograpf. Disponible en: https://es.scribd.com/document/507252742/Monograph-ofNASHA. XV. Cornejo P, Alcolea JM, Trelles MA. Perspectivas en el uso de materiales de relleno inyectables para tejidos blandos, desde nuestra experiencia. 1º parte. Cir Plast Iberolatinoam 2011;37(4):393-402. doi: 10.4321/S037678922011000400013. XVI. Day D, Littler C, Swift R, Gottlieb S. The Wrinkle Severity Scale. American Journal of Clinical Dermatology 2004;5:49-52. doi: 10.2165/00128071-200405010-00007. XVII. Dibernardo G, DiBernardo B. Prediction of treatment outcomes for neck rejuvenation Utilizing a unique classification system of treatment approach using a 1440-nm side-firing laser. Aesthetic Surgery Journal 2018;38:S43-S51. doi:10.1093/asj/sjy066. Ther 2022 XVIII. Sundaram H, Shamban A, Schlessinger J, Kaufman. Janette J, Joseph, JH, Lupin M, Draelos Z, Carey W, Smith S, Eaton L. Efficacy and safety of a new resilient hyaluronic acid filler in the correction of moderateto-severe dynamic perioral rhytides. A 52-week prospective, multicenter, controlled, randomized, evaluator-blinded study. Dermatol Surg. 2022 Jan 1;48(1):87-93. doi: 10.1097/DSS.0000000000003238. XIX. Abduljabbar MH, Basendwh MA. Complications of hyaluronic acid fillers and their managements. Journal of Dermatology & Dermatologic Surgery 2016;20(2). doi: 10.1016/j.jdds.2016.01.001. XX. Instrucciones de uso del producto Cientific Hyaluronic Facial Implant 30. Disponible en: https://es.scribd.com/document/265233528/Cientific-Hyaluronic-FacialImplant-30y18. XXI. Kaufman-Janette J, Taylor SC, Cox SE, Weinkle SH, Smith S, Kinney BM. Efficacy and safety of a new resilient hyaluronic acid dermal filler, in the correction of moderate-to-severe nasolabial folds. A 64-week, prospective, multicenter, controlled, randomized, doubleblind and within-subject study. J Cosmet Dermatol 2019 Oct;18(5):1244-1253. doi: 10.1111/jocd.13100. XXII. Dayan S, Maas CS, Grimes PE, Beer K, Monheit G, Snow S, Murphy DK, Lin V. Safety and effectiveness of VYC17.5L for long-term correction of nasolabial folds. Aesthet Surg J 2020 Jun 15;40(7):767-777. doi: 10.1093/asj/sjz200. Publisher An entity responsible for making the resource available Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 31/03/2025 Contributor An entity responsible for making contributions to the resource Allanmar International Company S.R.L Identifier An unambiguous reference to the resource within a given context DOI: https://doi.org/10.47196/0590 Claudio Dachevsky Cross-linked hyaluronic acid Effectiveness Facial rejuvenation Hyaluromax hyaluronic acid Marcelo Robles nasolabial folds safety https://ciencia.lugoneseditorial.com.ar/files/original/ef4ba9bbdbcc1ec82a9c1b060b807a95.pdf f8ffd7fbb7f17c1f9fb3ed328b475c9b Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/diabetes/freestyle-libre-2-plus/">https://lugoneseditorial.com.ar/diabetes/freestyle-libre-2-plus/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Exactitud comprobada con el sensor FreeStyle Libre 2 Plus Description An account of the resource Un nuevo estudio respalda la exactitud, y el uso seguro y confiable desde los 2 años de edad, con resultados comprobables desde el primer y hasta el último día de vida útil del sensor FreeStyle Libre 2 Plus Creator An entity primarily responsible for making the resource María Fernanda Cristoforetti, editora de Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 03/07/2025 Identifier An unambiguous reference to the resource within a given context <a href="https://doi.org/10.47196/0604">https://doi.org/10.47196/0604</a> Evidencia clínica Exactitud FreeStyle Libre 2 Plus MCG monitoreo continuo de glucosa Precisión seguridad Sistemas de monitoreo continuo de glucosa https://ciencia.lugoneseditorial.com.ar/files/original/37a93cbc15677d162bc3db847bc82f81.pdf 5e9f126e925d57252fa6089324399bad Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/hidroxiapatita-de-calcio-surcos-nasolabiales/">https://lugoneseditorial.com.ar/novedades/dermatologia/hidroxiapatita-de-calcio-surcos-nasolabiales/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Hidroxiapatita de calcio en surcos nasolabiales Description An account of the resource Evaluación de la seguridad y eficacia de la hidroxiapatita de calcio en el tratamiento de surcos nasolabiales. Creator An entity primarily responsible for making the resource Editora: María Fernanda Cristoforetti Source A related resource from which the described resource is derived I. Vera-Ramírez V, Morales-Sánchez MA, Santa-Cruz FJ, Medina-Bojórquez A. Escalas clínicas para evaluar el envejecimiento cutáneo: una revisión de la literatura. Rev Centro Dermatol Pascua 2021;2:68-75. doi: 10.35366/101176. II. Li K, Meng F, Li YR, Tian Y, Chen H, Jia Q, Cai H, Jiang HB. Application of nonsurgical modalities in improving facial aging. Int J Dent 2022 Feb 24;2022:8332631. doi: 10.1155/2022/8332631. III. Ogden S, Griffiths TW. A review of minimally invasive cosmetic procedures. Br J Dermatol 2008;159:1036-1050. doi: 10.1111/j.1365-2133.2008 .08845.x. IV. Sánchez-Carpintero I, Candelas D, Ruiz-Rodríguez R. Dermal fillers: types, indications, and complications. Actas Dermosifilogr 2010;101(5):381-393. doi: 10.1016/j. ad.2010.01.004 V. Bass LS, Smith S, Busso M, McClaren M. Calcium hydroxylapatite (Radiesse) for treatment of nasolabial folds: long-term safety and efficacy results. Aesthet Surg J 2010 Mar;30(2):235-8. doi: 10.1177/1090820X10366549. Ferreira Pacheco de Oliveira CS, da Silva Almeida TJ, de Oliveira-Martins L, Torelli Marques Sorpreso LA, Silveira Finck N. Hidroxiapatita de cálcio: uma revisão quanto àeficacia, segurança e imaginologia quando usado como preenchedor e como bioestimulador. Research Society and Development 2021;9(14):1-12. doi: 10.33448/ rsd-v10i14.21689. VII. Kadouch J. (2017). Calcium hydroxylapatite. A review on safety and complications. J Cosmet Dermatol 2017;16(2):152-161. doi: 10.1111/jocd.12326. VIII. Berlin A, Cohen JL, Goldberg DJ. Calcium hydroxylapatite for facial rejuvenation. Semin Cutan Med Surg. 2006 Sep;25(3):132-7. doi: 10.1016/j.sder.2006.06.005. IX. Tzikas TL. Evaluation of the Radiance FN soft tissue filler for facial soft tissue augmentation. Arch Facial Plast Surg 2004 Jul-Aug;6(4):234-9. doi: 10.1001/archfaci.6.4.234. X. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097. XI. Narins RS, Beer K. Liquid injectable silicone: a review of its history, immunology, technical considerations, complications, and potential. Plast Reconstr Surg 2006;118(3 Suppl):77S-84S. doi: 10.1097/01. prs.0000234919.25096.67. XII. Ahn MS. Calcium hydroxylapatite: Radiesse. Facial Plast Surg Clin North Am 2007 Feb;15(1):85-90. doi: 10.1016/j. fsc.2006.11.003. Publisher An entity responsible for making the resource available Lic. María Fernanda Cristoforetti, Editora de Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 08/07/2024 Rights Information about rights held in and over the resource Lugones Editorial Format The file format, physical medium, or dimensions of the resource Sitio web Language A language of the resource Español duración eficacia hidroxiapatita de calcio rellenos dérmicos seguridad surcos nasolabiales Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/terapia-oral-psoriasis-deucravacitinib/">https://lugoneseditorial.com.ar/novedades/dermatologia/terapia-oral-psoriasis-deucravacitinib/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Innovative oral therapy for psoriasis Description An account of the resource With high efficacy and a favorable safety profile, deucravacitinib is an innovative oral therapy for moderate to severe plaque psoriasis. Its oral route is a great advantage and promises to significantly improve the management of the disease. Creator An entity primarily responsible for making the resource Dr. Claudio Greco, Dermatologist, Member of the Psoriasis and Vitiligo Group of the Argentine Society of Dermatology, Coordinator of the Hidradenitis Suppurativa Group Source A related resource from which the described resource is derived I. Warren RB, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in plaque psoriasis. Psoriasis Area and Severity Index (PASI) outcomes over 4 years in patients receiving continuous deucravacitinib in the phase 3 POETYK PSO-1, PSO-2, and LTE trials. Presented at the 33rd European Academy of Dermatology & Venereology (EADV) Congress; 25-28 September 2024; Amsterdam, Netherlands. II. Warren RB, et al. Deucravacitinib in plaque psoriasis. 4-year efficacy results by prior biologic treatment in the phase 3 POETYK PSO-1, PSO-2, and LTE trials. Presented at the 33rd European Academy of Dermatology & Venereology (EADV) Congress; 25-28 September 2024; Amsterdam, Netherlands. III. Thaçi D, et al. Deucravacitinib efficacy in patients with moderate to severe psoriasis with scalp and fingernail disease. Response over 4 years of treatment in the phase 3 POETYK PSO-1, PSO-2, and LTE trials. Presented at the 33rdEuropean Academy of Dermatology & Venereology (EADV) Congress; 25-28 September 2024; Amsterdam, Netherlands. IV. Thaçi D, et al. Deucravacitinib efficacy in Psoriasis Area and Severity Index (PASI) target outcomes through 4 years in the phase 3 POETYK trials in moderate to severe plaque psoriasis Presented at the 33rd European Academy of Dermatology & Venereology (EADV) Congress; 25-28 September 2024; Amsterdam, Netherlands. V. Gooderham MJ, Hong CH, Litvinov IV. Selective TYK2 inhibition in the treatment of moderate to severe chronic plaque psoriasis. Skin Therapy Letter 2022;27(6). VI. Armstrong AW, Warren RB, Zhong Y, et al. Short-, mid-, and long-term efficacy of deucravacitinib versus biologics and nonbiologics for plaque psoriasis. A network meta-analysis. Dermatology and Therapy. 2023 Nov;13(11):2839-2857. Publisher An entity responsible for making the resource available Lic. María Fernanda Cristoforetti, Editor of Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource December 13th, 2024 Contributor An entity responsible for making contributions to the resource Bristol Language A language of the resource English Bristol Claudio Greco Deucravacitinib efficacy Oral therapy Dengue infection in diabetes Plaque psoriasis Psoriasis Safety profile https://ciencia.lugoneseditorial.com.ar/files/original/2d459bfdece07379bda495a2778217ba.pdf 08e3f3121b209b4913ca9183e352312a Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/inyecciones-botox-bienestar/">https://lugoneseditorial.com.ar/novedades/dermatologia/inyecciones-botox-bienestar/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Inyecciones de bótox y bienestar Description An account of the resource Revisión que analiza el impacto de las inyecciones de bótox en el bienestar psicológico y la calidad de vida. Source A related resource from which the described resource is derived Fuente: - Novo Pereiraa I, Hassan H. Impact of botulinum toxin for facial aesthetics on psychological well-being and quality of life: Evidence-based review. PRRAS 2020;75(12). Date A point or period of time associated with an event in the lifecycle of the resource 10/04/2025 Contributor An entity responsible for making contributions to the resource Import Velez Identifier An unambiguous reference to the resource within a given context <a href="https://doi.org/10.47196/0594">https://doi.org/10.47196/0594</a> Bienestar psicológico Bótox calidad de vida Import Velez Inyecciones de bótox Rejuvenecimiento facial Satisfacción Toxina botulínica Website A resource comprising of a web page or web pages and all related assets ( such as images, sound and video files, etc. ). Local URL The URL of the local directory containing all assets of the website <a href="https://lugoneseditorial.com.ar/novedades/diabetes/diabetes-congreso-ada-2024/" target="_blank" rel="noreferrer noopener">https://lugoneseditorial.com.ar/novedades/diabetes/diabetes-congreso-ada-2024/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource La detección y prevención de la diabetes, su diagnóstico y tratamiento, sus complicaciones y comorbilidades asociadas, y el rol de la inteligencia artificial fueron algunos de los temas del Congreso ADA 2024. Entrevista con el Dr. León Litwak, Médico especialista en Endocrinología, Hospital Italiano de Buenos Aires Description An account of the resource Del 21 al 24 de junio de 2024 se celebraron las 84º Sesiones Científicas de la American Diabetes Association (Congreso ADA 2024), en Orlando (Florida), donde se presentaron múltiples novedades referidas a la detección precoz y la prevención, particularmente de la diabetes tipo 1 (DT1), el diagnóstico y tratamiento de las diferentes áreas relacionadas con la DM y la obesidad, las complicaciones y comorbilidades asociadas a la DM y la incorporación gradual de la inteligencia artificial en el campo de la diabetología. Creator An entity primarily responsible for making the resource Cristoforetti, María Fernanda Publisher An entity responsible for making the resource available Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 02.08.24 Contributor An entity responsible for making contributions to the resource Litwak, León American Diabetes Association Language A language of the resource Esp complicaciones Congreso ADA 2024León Litwak Diabetes Inteligencia artificial y comorbilidades asociadas https://ciencia.lugoneseditorial.com.ar/files/original/b25563ea341d339062a68bd4de9e6c22.pdf 4bdc966b5180353582173cadbebe4e35 Hyperlink A link, or reference, to another resource on the Internet. URL https://lugoneseditorial.com.ar/destacada/linfoma-cutaneo-t-diagnostico/ Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Linfoma cutáneo T, un verdadero desafío diagnóstico Description An account of the resource El linfoma cutáneo T es una patología aún incurable, pero compatible con una larga sobrevida, en parte gracias al arsenal terapéutico actualmente disponible. También se destaca el valor del trabajo mancomunado entre el hematólogo y el dermatólogo para el adecuado seguimiento del paciente. Creator An entity primarily responsible for making the resource María Fernanda Cristoforetti Publisher An entity responsible for making the resource available Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 08/04/2024 Contributor An entity responsible for making contributions to the resource Takeda Anatomía patológica Dermatología Diagnóstico Hematología Linfoma cutáneo T Multidisciplinario Takeda Terapias sistémicas https://ciencia.lugoneseditorial.com.ar/files/original/a722a992e3188d3b542d1f7408ad2425.pdf 706d8ebce706d0dcecbe09b3f98cb768 Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-labios/">https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-labios/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Lip volumization with cross-linked hyaluronic acid 18 mg/ml. Efficacy and safety in 102 treated patients Description An account of the resource Introduction: beauty trends have increased the demand for aesthetic procedures, especially the use of hyaluronic acid (HA), to rejuvenate the face and enhance lips. This safe and effective treatment hydrates, fills wrinkles, and restores volume to different areas of the face. HA is obtained from non-animal sources, is non-immunogenic, and possesses antioxidant properties. The perioral region, key to facial aging, is highly sought after for correcting wrinkles, folds, and the loss of definition caused by factors such as age, sun exposure, and lifestyle habits. Cross-linked hyaluronic acid (HRA) is an ideal option for restoring volume to this area. Objectives: to evaluate the safety, efficacy and adverse effects of using HRA 18 mg/ml as a lip filler. Materials and methods: a prospective clinical study included 102 patients (81 women and 21 men), aged 25–65, who required lip volumization and received Cientific Hyaluronic Facial Implant 18® (HRA 18 mg/ml). Treatment efficacy was assessed using the Global Aesthetic Improvement Scale (GAIS). Initial lip volume and perioral wrinkle severity were assessed using the photonumeric scales MERZ (Merz Lip Fullness Scale, MLFS) and Wrinkle Severity Rating Scale (WSRS), respectively. Safety was determined by analyzing local reactions at the injection site and the occurrence of adverse events. The product was administered at a dose of up to 1 ml per half of the lip in an initial application (T0), with follow-ups at 1, 3, and 8 months. If necessary, a single reapplication was performed during these follow-ups. Treatment efficacy was assessed at a final follow-up at 12 months. Results: adverse effects were mild, of immediate onset, common for this type of treatment, which resolved without the need for special treatment. The volumizing effect of HRA 18 mg/ml was effective in 98% of treated patients, with a gradual decrease after 12 months. A significant improvement in lip hydration and firmness was observed. Conclusions: HRA 18 mg/ml is a safe and effective treatment as a dermal filler in lips, with high volume retention and lasting up to 12 months. Patients and professionals experienced high satisfaction, and improvements in skin firmness and elasticity were observed. The results support HRA as a viable and beneficial option in aesthetic medicine. Creator An entity primarily responsible for making the resource Claudio Dachevsky Date A point or period of time associated with an event in the lifecycle of the resource 12/05/2025 Contributor An entity responsible for making contributions to the resource Allanmar Identifier An unambiguous reference to the resource within a given context <a href="https://doi.org/10.47196/0595">https://doi.org/10.47196/0595</a> hyaluronic acid lips perioral area volumization Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/diabetes/monitoreo-continuo-de-glucosa/">https://lugoneseditorial.com.ar/novedades/diabetes/monitoreo-continuo-de-glucosa/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Monitoreo continuo de glucosa: nuevo portal de diabetes Description An account of the resource En el nuevo Portal Abbott Diabetes destacados especialistas dictan cursos certificados y on demand sobre los últimos avances en monitoreo continuo de glucosa y tecnología aplicada a la diabetes. Exclusivo para profesionales de la salud. Publisher An entity responsible for making the resource available Lic. María Fernanda Cristoforetti, Editora de Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 16 diciembre, 2024 Contributor An entity responsible for making contributions to the resource Abbott Diabetes Adrián Proietti Alejandro Dain Aspectos clave del uso del monitoreo continuo de glucosa Cursos certificados Cursos on demand Diabetes Florencia Siufi FreeStyle Libre Gabriela Rovira Laura Kabakian LibreView María Ruiz monitoreo continuo de glucosa Portal Abbott Diabetes Portal médico Tecnología aplicada a la diabetes